Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab PK/Safety in Healthy Japanese and Caucasian Subjects
NCT05305222Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risankizumab in plaque psoriasis (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events up to 137 days, Maximum Observed Plasma Concentration up to 137 days and 5 more. Started Oct 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05305222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305222.